Docusign Inc vs Nuwellis Inc — how do they compare? Docusign Inc trades at $57.83 (market cap $11.33B), while Nuwellis Inc trades at $1.49 (market cap $542.80K). The key difference: Docusign Inc is far larger — about 20873.2× Nuwellis Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | NUWE | |
|---|---|---|
Market Cap | $11.33B | $542.80K |
Sector | Technology | Technology |
52-Week High | $85.01 | $220.50 |
52-Week Low | $41.75 | $1.42 |
Enterprise Value | $10.70B | -$1.27M |
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $59.64, down 1.03% today but maintaining strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $2.8B in 2024 to $3.0B in 2025 and impressive net income margin expansion to 35.87%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.09 surpassing the $0.994 estimate. Institutional activity shows mixed signals with some funds reducing positions while others increase exposure.
DOCU presents a compelling growth story with strong profitability metrics and consistent earnings beats, though valuation remains elevated at 38.53 P/E. The stock faces near-term resistance at $60-$62 levels with overbought RSI conditions. Analyst consensus leans cautious with 67.86% hold ratings, suggesting potential consolidation before further upside. Key risks include competitive pressures in e-signature space and execution challenges in maintaining current growth trajectory.
No Aura AI signal available yet.
Trailing returns across standard periods
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →